Business Context and Reporting Period
This Form 8-K, dated September 4, 2026, reports the completion of an acquisition by Tarsus Pharmaceuticals, Inc. (TARS). On this date, Tarsus finalized the acquisition of Alkeus Pharmaceuticals, Inc. (Alkeus) pursuant to a Merger Agreement dated July 31, 2026. Alkeus now operates as a wholly-owned subsidiary of Tarsus.
Key Financial Metrics and Transaction Terms
The transaction involved significant upfront consideration and contingent future payments:
- Up-Front Cash Consideration: $270,000,000 (subject to customary adjustments and a post-closing purchase price adjustment).
- Up-Front Stock Consideration: 2,908,692 shares of Tarsus Common Stock issued to Alkeus equityholders.
- Milestone Payments: Up to $350,000,000 total.
- $250,000,000 payable in cash and/or stock upon U.S. regulatory approval of an Alkeus product.
- $100,000,000 payable in cash upon the first U.S. sale of an Alkeus product.
- Revenue Sharing: Tiered payments in the low-to-mid single digits as a percentage of future annual worldwide gildeuretinol net sales.
Note: This filing does not provide Tarsus's standalone revenue, profit, cash flow, or debt metrics for the reporting period. Pro forma financial information is scheduled to be filed within 71 days.
Material Changes
The primary material change is the consolidation of Alkeus Pharmaceuticals into Tarsus. This transaction significantly alters the company's asset base and potential future revenue streams through the addition of Alkeus's product pipeline, specifically gildeuretinol. The company has incurred a substantial immediate cash outflow of $270 million and issued new equity, which will impact liquidity and capitalization.
Outlook, Risks, and Contingencies
Future Obligations: The company faces significant contingent liabilities totaling up to $350 million in milestone payments and ongoing revenue sharing obligations. These payments are contingent upon regulatory approvals and commercial sales, introducing execution risk.
Financial Reporting: Required financial statements of the acquired business and pro forma financial information are not included in this report and will be filed via amendment within 71 calendar days.
Confidentiality: Certain portions of the Merger Agreement and related exhibits have been redacted for confidentiality.
Investor Verification Checklist
- Verify the impact of the $270 million cash outflow on Tarsus's current liquidity and cash runway.
- Review the upcoming pro forma financial statements (due within 71 days) to assess the combined entity's financial health.
- Confirm the specific terms and conditions attached to the $350 million in milestone payments and revenue sharing.
- Monitor the development status of Alkeus's gildeuretinol product to evaluate the likelihood of triggering future payments.
- Check for any dilution effects resulting from the issuance of 2,908,692 new shares.